NervGen Pharma develops first-in-class neuroreparative therapeutics that target biological barriers to nervous system repair. Its lead candidate, NVG-291, is a peptide in clinical development for spinal cord injury and other neurotraumatic conditions, supported by technology licensed from Case Western Reserve University.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -4 | — |
| Q2 2025 | 0 | — | -9.1 | — |
| Q3 2025 | 0 | — | -4.2 | — |
| Q4 2025 | 0 | — | -26.9 | — |
| Q1 2026 | 0 | — | -1.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Imperial Petroleum Inc. (IMPP), National CineMedia, Inc. (NCMI), Melar Acquisition Corp. I (MACI), Twelve Seas Investment Company III (TWLV), Chicago Atlantic BDC, Inc. (LIEN), Adagene Inc. (ADAG)